Most T lymphocytes express the hypervariable, heterodimeric ␣␤ T-cell receptor (TCR) 1 that is noncovalently associated with CD3 subunits ␥, ␦, ⑀, and TCR-, responsible for signal transduction. [2] [3] [4] [5] The chain exists as a homodimer within the CD3 complex, 6 with each chain containing 3 immunoreceptor tyrosine-based activation motifs (ITAMs). Cross-linking of TCRs initiates a signaling cascade mediated by Src family tyrosine kinases, resulting in phosphorylation of ITAMs, and subsequent T-cell activation. [7] [8] [9] [10] [11] Studies in which the extracellular domains of molecules involved in immune system activation were fused to the chain, thereby creating chimeras such as Fv, CD4, CD8, and interleukin-2 receptor ␣ (IL-2R␣)-, [7] [8] [9] [12] [13] [14] have shown that chains, as monomers, and in the absence of the remainder of the CD3 complex, can transduce signals in T cells. For example, an IAchimeric construct was found sufficient for activation of both naive and memory CD4 ϩ and CD8 ϩ T cells and for their differentiation into Th1 and Th2 subsets. These functions were elicited by antibody (Ab)-induced cross-linking and were independent of the TCR or other CD3 complex components. 15 Thus, a chain chimera has the potential to act as a surrogate TCR. In addition to using -immune receptor chimeras to explore the effects on cell signaling and lymphocyte development, chimeras have been used to redirect killing activity, eliminating only those cells binding to the external domains of the chimeric molecule. For example, CD8 ϩ T cells or natural killer (NK) cells expressing a CD4-fusion protein [13] [14] [15] [16] were activated by and specifically killed HIV gp120-expressing cells in vitro via a CD4-gp120 interaction, and cytotoxic T lymphocyte (CTL)-expressing Fv(␣ErbB-R2)--chimeric protein killed ErbB-R2-expressing target cells and retarded tumor cell growth in nude mice.
Introduction
Most T lymphocytes express the hypervariable, heterodimeric ␣␤ T-cell receptor (TCR) 1 that is noncovalently associated with CD3 subunits ␥, ␦, ⑀, and TCR-, responsible for signal transduction. [2] [3] [4] [5] The chain exists as a homodimer within the CD3 complex, 6 with each chain containing 3 immunoreceptor tyrosine-based activation motifs (ITAMs). Cross-linking of TCRs initiates a signaling cascade mediated by Src family tyrosine kinases, resulting in phosphorylation of ITAMs, and subsequent T-cell activation. [7] [8] [9] [10] [11] Studies in which the extracellular domains of molecules involved in immune system activation were fused to the chain, thereby creating chimeras such as Fv, CD4, CD8, and interleukin-2 receptor ␣ (IL-2R␣)-, [7] [8] [9] [12] [13] [14] have shown that chains, as monomers, and in the absence of the remainder of the CD3 complex, can transduce signals in T cells. For example, an IAchimeric construct was found sufficient for activation of both naive and memory CD4 ϩ and CD8 ϩ T cells and for their differentiation into Th1 and Th2 subsets. These functions were elicited by antibody (Ab)-induced cross-linking and were independent of the TCR or other CD3 complex components. 15 Thus, a chain chimera has the potential to act as a surrogate TCR. In addition to using -immune receptor chimeras to explore the effects on cell signaling and lymphocyte development, chimeras have been used to redirect killing activity, eliminating only those cells binding to the external domains of the chimeric molecule. For example, CD8 ϩ T cells or natural killer (NK) cells expressing a CD4-fusion protein [13] [14] [15] [16] were activated by and specifically killed HIV gp120-expressing cells in vitro via a CD4-gp120 interaction, and cytotoxic T lymphocyte (CTL)-expressing Fv(␣ErbB-R2)--chimeric protein killed ErbB-R2-expressing target cells and retarded tumor cell growth in nude mice.
The development of specific immunotherapies to prevent graft rejection and graft-versus-host disease (GVHD) (reviewed in Yu et al 17 ) offers the promise of specifically deleting only those immune responses directed to the allospecificities of the graft. An unexplored approach to the generation of alloantigen-specific tolerance is the development of an "enhanced" veto cell. Veto cells are antigen-presenting cells (APCs), which inactivate or kill cells binding to alloantigen on their surface. 18 Veto activity involves direct cell-cell interaction, is most potently mediated by CD8 ϩ CTLs, 19, 20 and results in anergy or deletion of allospecific T cells. 18, [21] [22] [23] The hallmark of veto cell interactions is unidirectional recognition: the TCR of the CTL recognizes the veto cell, but the specificity or even the existence of TCRs on a veto cell is irrelevant to veto activity, albeit veto activity has been shown to be augmented by concomitant TCR stimulation. 24 Thus, we reasoned that providing TCR-like signaling to allogeneic major histocompatibility complex (MHC) on the surface of CD8 ϩ CTLs might result in enhanced veto function. Here, we evaluate the immunologic effects of transgenic expression of a novel D d -fusion protein. We describe the generation and characterization of a novel memory CTL-like killer cell that lacks both TCR and CD8. Splenocytes from D d -transgenic mice exhibit veto function in vitro by potently and specifically inhibiting the in vitro generation of D d -specific CTL responses. Future studies will consider the in vivo activity of these cells in models of graft rejection and GVHD.
Materials and methods D d -construct
A chimeric protein, D d -, was created by joining the extracellular and transmembrane portions of the mouse H-2D d molecule with the cytoplasmic portion of the mouse chain (a kind gift from Alan Weissman, NCI, NIH, Bethesda, MD). The D d extracellular and transmembrane domains were derived by polymerase chain reaction (PCR) from a D d cDNA, pD d SEL.FIX34 (a kind gift from Dr Randy Ribaudo, Molecular Applications Group, Palo Alto, CA). The PCR reaction was performed using a forward primer that corresponded to the 5Ј end of the D d cDNA and a reverse primer that corresponded to the 3Ј end of the D d transmembrane domain and contained an EcoRI restriction cleavage site. The primers used in the PCR reaction of D d are as follows: forward primer, 5Ј-TAAATTCTCGAGGGATCCCAGATGGGGGCG-3Ј; reverse primer, 5Ј-CTGCACGAATTCTCTCCTCCTCTTCATCAC-3Ј. The mouse intracellular region was obtained by PCR from pGEM 7Zfϩ. 25 The sequences of DNA primers used were the following: 5Ј-TCGTATGAATTCGCAAAAT-TCAGCAGGAGTGCAGAG-3Ј, which is present in the intracellular domain and engineered in an EcoRI restriction cleavage site, and 5Ј-CTAGCTAGATCTAAGCTTGCATGCCTGCAGGTCGAC-3Ј, present in the polylinker sequence of pGEM 7Zfϩ, which is 3Ј of the zeta cDNA. 28 respectively. Prior to ligation into the p29⌬2(Sal Ϫ ) vector, the polyadenylation signal sequence was removed from the end of the D d -construct to allow the chimeric construct to use the poly (A) signal sequences derived from the p29⌬2(Sal Ϫ ) vector.
Transfections
The Jurkat and EL-4 cell lines were transfected by electroporation with 10 g linearized CD2-D d or CD2-D d -plasmid and 1 g linearized pFNeo, a plasmid carrying a neomycin resistance gene for selection, 29 and cloned by limiting dilution. Transfectants used for study were selected according to surface expression of D d assessed by immunofluorescence and flow cytometry.
Animals
Mice were bred in house or purchased from Taconic Farms (Germantown, NY). All procedures involving animals were performed after review and approval by the Center for Biologics Evaluation and Research (CBER) Institutional Animal Care and Use Committee.
Generation of transgenic mouse lines
Pronuclear injections were performed on fertilized FVB/N oocytes as described. 30 Transgenic animals were produced using the CD2- 28 The MHC haplotype of FVB/N mice is H-2 q .
Immunofluorescent staining and flow cytometry
Flow cytometry was performed as described. 31 Cells to be stained were first incubated with unlabeled monoclonal antibody (mAb) to Fc receptors (2.4G2). Background staining was evaluated using fluorochromeconjugated rat immunoglobulin G2a (IgG2a) mAb controls, with the exception of the allophycocyanin control, which is conjugated to a mouse IgG1 mAb. Cells were analyzed using Becton Dickinson Immunocytometry Systems (Mountain View, CA) fluorescence-activated cell sorter scan (FACScan) or FACSCalibur using CellQuest software. Cell sorting was done on a FACStar Plus . Other antibodies used for flow cytometry were obtained from BD PharMingen (San Diego, CA) and included anti-CD3⑀
, anti-Pan-NK cells (DX5), anti-Ly-49A B6 (A1), anti-Ly-49A and Ly-49D (12A8), anti-Ly-49C and Ly-49I (5E6), anti-Ly-49D (4E5), and anti-Ly-49G2 (4D11).
In vitro assays for lymphocyte function
Mixed lymphocyte reaction (MLR) at a 1:1 stimulator-to-responder ratio 32 and 51 Cr release cytotoxicity assays were performed as described. 33 Proliferation was evaluated by 3 H-thymidine (Perkin Elmer, Boston, MA) uptake 32 or by dilution of carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR). 34 Approximately 1 ϫ 10 7 cells to be labeled were pelleted and resuspended in 1 mL phosphate-buffered saline (PBS; Biofluids, Rockville, MD) containing 250 ng/mL CFSE and were incubated at 37°C in the dark with shaking for 15 minutes. The cells were then washed twice with RPMI 1640 (Biofluids) containing 10% fetal bovine serum (Hyclone, Logan, UT) (complete medium, CM) and stimulated as described for individual experiments. After the incubation period, the cells were washed twice and resuspended in CM containing 10 ng/mL phorbolmyristate acetate (PMA; Sigma, St Louis, MO). The cells were then plated at 1 ϫ 10 5 cells/well in a 96-well flat-bottom plate that had been previously coated with a rabbit antimouse IgG antibody (Cappel/Organon Teknika, West Chester, PA). The plate was then centrifuged for 2 minutes at 100g. After centrifugation, the cells were incubated for 24 hours in a humidified CO 2 incubator at 37°C. Cell-free supernatants were collected from the wells. The IL-2-dependent mouse cell line, CTLL-2 (ATCC), was used to determine the presence of IL-2 in the supernatants as described. 35 
Interleukin-2 (IL-2) assay

Skin grafting
Mice were engrafted on the flank with tail skin from donor mice as described. 36 Grafts were scored daily until rejected (Ͼ 80% loss of graft tissue).
Results
D d -chimeric construct
To construct a class I MHC molecule with enhanced signaling capabilities, we created a chimeric gene, consisting of the extracel- Although these CD3 Ϫ CD5 ϩ D d high cells did not express ␣/␤ or ␥/␦ TCR, CD4, or CD8, they appeared to be of T-cell lineage as they expressed Thy-1, failed to express hematolymphoid lineagespecific markers (CD34, B220, CD11b, CD19, DX5, or CD11c; unpublished observations, December 11, 1998), and, most intriguingly, expressed markers characteristic of memory CD8 ϩ CTLs, including high levels of CD44, Ly-6C, and CD122 [38] [39] [40] (Figure 6 ). The number of CD3 Ϫ CD5 ϩ cells correlated with the dose of the transgene, with almost none found in the 6657 line, 17% in the spleens of 130 heterozygotes, and 25% in the spleens of 130 homozygotes ( Figure 5A ). As the combined percentages of CD3 Ϫ CD5 ϩ cells and CD4 ϩ /CD8 ϩ T cells in the D d -mice approximated the expected percentage of splenic T cells (about 46%), it is tempting to speculate that development of single positive T cells was thwarted by a signaling event through the chain in the thymus that generated CD3 Ϫ CD5 ϩ lymphocytes. Evidence to support this possibility is offered by the increased percentage of double negative (DN) thymocytes in D d -mice, which express CD44 and Ly-6C ( Figure 7 ). In addition, many of the CD44 ϩ and Ly-6C ϩ thymocytes bear high levels of CD5 and CD25, a phenotype suggestive of recent activation (Figure 7) . 41 We next asked whether signaling through could activate 
Effects of D d -cells on allogeneic T-cell responses in vitro
The activation of Figure  12 ). Although binding of these mAbs in FVB mice has not been studied in detail, this strain is closely related to the 129 strain and likely has the 129 strain-related NK complex [50] [51] [52] [53] for which these Abs have been studied extensively. Coupled with the observation that only a slight reduction (7.5%) of DX5 ϩ cells was observed in MHC-D d (Figure 12 ) and CD2-D d transgenic mice (unpublished observations, February 22, 2000) , as compared to parental FVB, these data strongly suggest that cells capable of binding to D d may be specifically eliminated in D d -mice in vivo.
Discussion
Our intent in constructing an MHC-fusion molecule was to generate CD8 ϩ CTLs with enhanced veto activity directly from Stimulator and responder splenocytes were incubated in MLC at a 1:1 ratio for 5 days, harvested, and tested against 51 41, 54, 55 Furthermore, the lack of TCRs on DN cells of D d -mice we think is attributable to the suppression of RAG gene expression, observed in cells following aberrant or premature signaling through . Evidence supporting these possibilities comes from studies of mice transgenic for a full-length chain (FL ) under the control of the CD2 promoter/ enhancer. 27 It was found that overexpression of FL caused premature termination of RAG-1 and RAG-2 production, preventing productive rearrangements of TCR ␣ and ␤, thus blocking entry into the DP pathway. The cellular populations in the FL mice were very similar to those found in our mice, with increased numbers of CD5 hi DN cells and reduced DP, CD4 SP, and CD8 SP populations, indicating a developmental block at the DN stage of thymic development. 27 In the periphery, we found a large population of cells with a phenotype identical to D d -DN thymocytes, except that they lacked CD25 expression. These cells bear a striking resemblance to memory CTLs, and to homeostatically expanding cells (CD44 ϩ , Ly-6C ϩ , and CD122 ϩ ), with the exception that they lack TCRs and CD8. [56] [57] [58] 59 the diminished expression was shown to be due to down-modulation of Ly-49 and not to decreased NK cell numbers. 60 context of H-2D d (P815 mastocytoma). That we have observed a sizable but not complete elimination of alloreactive CTLs in these cultures suggests that some alloreactive CTLs may not recognize D d plus self-peptide with sufficient affinity to activate the veto cells. Whether a substantial reduction in alloreactivity can be achieved in vivo, and, if so, whether it will inhibit allograft rejection, remain to be seen.
By expressing an allo-MHC molecule with signaling capability in transgenic mice, a population of unique veto killer cells was generated that lack TCRs and CD8 or CD4, but express Thy-1 and an array of memory CTL-like activation markers. These cells can be activated by allo-specific TCRs and can efficiently kill cells capable of recognizing the alloantigen on their surface. It is apparent that our CD3 Ϫ CD5 ϩ memory CTL-like cells would theoretically serve as ideal veto cells for the prevention of graft rejection, because they mediate potent veto activity but lack the equipment (TCRs) for mediating classical GVHD. However, the question arises as to whether such cells can be generated in healthy animals. Support for such a possibility includes studies from Sabapathy et al, 62 who described a population of killer cells with phenotypic similarity to our CD3 Ϫ CD5 ϩ memory CTLs (CD3 Ϫ CD5 ϩ Thy1 ϩ Ly-6C ϩ ) that killed tumor targets in vitro. However, the routine ability to generate such cells from different strains of mice is unclear; therefore, a gene therapy approach may be more successful. Such studies are under way.
